Log in to search using one of your social media accounts:

 

Drugmakers see a pricing blueprint in an $850,000 gene therapy

SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech's $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Nature Biotechnology 36, 6 (2018). doi:10.1038/nbt0118-6a
Source: Nature Biotechnology - Category: Biotechnology Tags: News Source Type: research
by Craig Klugman, Ph.D. The FDA has approved the world’s first gene therapy: Luxturna (voretigene neparvovec; AAV2-hRPE65v2) is a one-time intervention that can treat an inherited retinal disease (RPE65-mediated inherited retinal dystrophy). The disease is rare, affecting only 1,000-2,000 people in the U.S. The treatment works by introducing a virus to the eye that contains a healthy copy of the gene that caused the blindness. In a phase 3 trial of 31 subjects (20 intervention; 9 control; 2 withdrew), 65% of patients who received the procedure experienced dramatic improvements in their vision.…
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Clinical Trials & Studies Featured Posts Health Disparities Health Policy & Insurance Health Regulation & Law Pharmaceuticals gene therapy Luxturna Source Type: blogs
Drug-maker Spark Therapeutics lowered the cost of its treatment for a rare form of blindness from $1 million, but at $850,000, the drug is still one of the most expensive gene therapies in the world.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
(Reuters) - Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Drugmaker says it lowered cost of treatment approved by the FDA last month, citing insurer concerns
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
The Philadelphia company will offer outcomes-based rebates and the possibility for installment payments to help ensure access to the one-time therapy that treats a condition that otherwise leads to blindness.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
(Reuters) - Spark Therapeutics Inc said on Wednesday it would charge $850,000 per patient for its gene therapy to treat a rare form of blindness, lesser than analysts' expectation of around $1 million.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Luxturna is most expensive treatment on market and price raises affordability questions
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Blindness | Gene Therapy | Genetics | Health | Opthalmology